Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.66 |
| ▸ | PLG | P00747 | 1/20 | 0.62 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.61 |
| ▸ | FLT3 | P36888 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | CDK8 | P49336 | 2/20 | 0.60 |
| ▸ | CCNC | P24863 | 1/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421600 | 0.92 | ABCG2 (0.67) | MAPTABCB1NPC1CYP3A4CYP2C9 | |
| SCHEMBL7306849 | 0.89 | MAPT (0.74) | MAPTABCB1NPC1CYP3A4CYP2C9 | |
| Corymbosin SCHEMBL1421623 | 0.88 | MAOB (0.56) | MAPTABCB1NPC1CYP3A4CYP2C9 | |
| SCHEMBL29845342 | 0.87 | CYP1B1 (0.86) | MAPTABCB1NPC1CYP3A4CYP2C9 | |
| SCHEMBL1421382 | 0.87 | CYP1B1 (0.86) | MAPTABCB1NPC1CYP3A4CYP2C9 | |
| SCHEMBL24514602 | 0.86 | CYP1A1 (0.75) | MAPTABCB1ABCG2CYP1B1FLT3 | |
| Methane SCHEMBL27890494 | 0.86 | CYP1B1 (0.84) | MAPTABCB1NPC1CYP3A4CYP2C9 | |
| SCHEMBL27907057 | 0.86 | CYP1B1 (0.84) | MAPTABCB1NPC1CYP3A4CYP2C9 | |
| SCHEMBL24514601 | 0.85 | ABCB1 (0.73) | ABCB1ABCG2CYP1B1CYP1A1CYP1A2 | |
| SCHEMBL1976409 | 0.85 | CYP1A1 (0.59) | MAPTABCB1ABCG2CYP1B1IP6K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AXOGLIA THERAPEUTICS (LU) | 2011-06-16 | — | — | US | disclosed |
| EP-2112145-A1 | Chromenone derivatives useful for the treatment of neurodegenerative diseases | AxoGlia Therapeutics S.A. (LU) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, CDR2, SNCA | MAPT 243/4885ABCB1 2178/4885NPC1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.